Pyrvinium is effective in inducing apoptosis, inhibiting colony formation and self-renewal capacity of CD34+ cells from TKI-resistant BP-CML patients, while cord blood CD34+ are largely unaffected. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.